Lv3
220 积分 2023-11-09 加入
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
1小时前
求助中
Correction to Lancet Neurol 2021; 20: 526–36
7天前
已完结
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
7天前
已完结
Safety and outcomes with efgartigimod use for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practice
1个月前
已完结
FcRn Inhibitor Therapies in Neurologic Diseases
1个月前
已完结
Perioperative Safety and Efficacy of Efgartigimod for Thymoma associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial
1个月前
已完结
Targeting HIF-1α alleviates the inflammatory responses and rebuilds the CD4+ T cell subsets balance in the experimental autoimmune myasthenia gravis inflammation model via regulating cellular and humoral immunity
1个月前
已完结
Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)
2个月前
已关闭
Study of the prevalence of familial autoimmune myasthenia gravis in a Spanish cohort
2个月前
已完结
SIRT3 inhibits fibroblast-like synoviocytes activation in rheumatoid arthritis through delactylation of H3K18
3个月前
已完结
皖公网安备34019202002308
